http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 19 Feb 2026 01:00:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of February 19, 2026: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 93,743,243 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwalignl bwpadl2" rowspan="1" colspan="1"><p class="bwcellpmargin bwalignl"> 6,140 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+February+19%2C+2026/26024745.html Thu, 19 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Press+Releases/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one meetings at the following conference: </p><p> <b>Leerink Partners Global Healthcare Conference 2026</b> </p><ul class="bwlistdisc"> <li> Dates: March 8–11, 2026 </li> <li> Location: Miami, Florida, United States </li> </ul><p> Fireside chat: </p><ul class="bwlistdisc"> <li> Date: March 9, 2026 </li> <li> Time: 3:40 PM ET / 8:40 PM CET </li> <li> To enter the live webcast, please <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fevent.summitcast.com%2Fview%2FmT9poctHDNthc6b89WqVjf%2Fguest_book%3Fsession_id%3DHGgKAfU45BdRB8cJwMy6dJ&amp;esheet=54427068&amp;newsitemid=20260217839115&amp;lan=en-US&amp;anchor=click+here&amp;index=1&amp;md5=e6032d96389ba139588185cbe4395389" shape="rect">click here</a> </li> </ul><p> The link to access the live webcast of the presentation will be available on the <a http://www.streetinsider.com/Business+Wire/Innate+Pharma+to+Participate+in+the+Leerink+Partners+Global+Healthcare+Conference/26016445.html Wed, 18 Feb 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 93,719,323 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 6,324 Preferred Shares 2016 </p> <p class="bwcellpmargin"> 7,581 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html Wed, 07 Jan 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 93,719,323 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 6,324 Preferred Shares 2016 </p> <p class="bwcellpmargin"> 7,581 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html Wed, 07 Jan 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 93,719,323 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 6,324 Preferred Shares 2016 </p> <p class="bwcellpmargin"> 7,581 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html Wed, 07 Jan 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 93,719,323 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 6,324 Preferred Shares 2016 </p> <p class="bwcellpmargin"> 7,581 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html Wed, 07 Jan 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html <p> MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “<b>AMF</b>”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“<b>Innate</b>” or the “<b>Company</b>”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2025: </p><table cellspacing="0" class="bwtablemarginb bwblockalignl"> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> Total number of shares outstanding: </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 93,719,323 ordinary shares </p> </td> </tr> <tr> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin">   </p> </td> <td class="bwvertalignt bwpadl0" rowspan="1" colspan="1"><p class="bwcellpmargin"> 6,324 Preferred Shares 2016 </p> <p class="bwcellpmargin"> 7,581 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+Innate+Pharma+as+of+December+31%2C+2025/25815771.html Wed, 07 Jan 2026 01:00:00 +0000 A.26800952 IPH IPHA O.00380011 O.00711722